Medical Device Combines Nanotechnology to Diagnose Kidney Disease
|
By LabMedica International staff writers Posted on 17 Mar 2015 |

Image: The quantitative electrochemical lateral flow assay (QELFA) device (Photo courtesy of Somersault 18:24).
A new medical device which combines nanotechnology with a pregnancy tester could help diagnose and treat the one million people in the UK who don't know they have kidney disease.
Every day 19 people in the UK are diagnosed with kidney failure yet there is currently no device that can be used by doctors for day-to-day monitoring of kidney disease and four of the 19 people will not have visited specialist services for sufficient time to prepare for their treatment.
The apparatus is a quantitative electrochemical lateral flow assay (QELFA) and uses nanoparticles to test the patient's urine giving results in seconds. It is linked via mobile technology so doctors can track how the disease is developing. The devise was developed by engineers and costs about GBP 10 can be used at home and could revolutionize kidney disease care in the UK, which currently costs the UK National Health Service (NHS) over GBP 1.4 billion, more than breast, lung, colon and skin cancer combined.
The devise which works like a pregnancy test was created by Bio Nano Consulting (London, UK). The digital readout of the test enables the automatic and accurate collation of kidney-function readings into a central database using mobile technology. Behind the patients who develop kidney failure and in need of rapid diagnosis are many more who will have a lesser degree of kidney dysfunction, called Chronic Kidney Disease (CKD), that will place them at increased risk of cardiovascular disease and acute kidney injury.
Helen Meese CEng, MIMech, PhD, Head of Materials at the Institution of Mechanical Engineers (London, UK), said, “The QELFA device is a brilliant example of what's possible. Using an old technology like a pregnancy tester and combining it with nanotechnology, you have a device which could not only diagnose the million people in the UK who are unaware they have kidney disease, but also help doctors effectively monitor those undergoing treatment. It could also save the NHS millions of pounds a year. But although the UK has been at the forefront of nanotechnology development, we still lag behind in its commercialization and many people are still unsure of its potential. We must change this.”
Related Links:
Bio Nano Consulting
Institution of Mechanical Engineers
Every day 19 people in the UK are diagnosed with kidney failure yet there is currently no device that can be used by doctors for day-to-day monitoring of kidney disease and four of the 19 people will not have visited specialist services for sufficient time to prepare for their treatment.
The apparatus is a quantitative electrochemical lateral flow assay (QELFA) and uses nanoparticles to test the patient's urine giving results in seconds. It is linked via mobile technology so doctors can track how the disease is developing. The devise was developed by engineers and costs about GBP 10 can be used at home and could revolutionize kidney disease care in the UK, which currently costs the UK National Health Service (NHS) over GBP 1.4 billion, more than breast, lung, colon and skin cancer combined.
The devise which works like a pregnancy test was created by Bio Nano Consulting (London, UK). The digital readout of the test enables the automatic and accurate collation of kidney-function readings into a central database using mobile technology. Behind the patients who develop kidney failure and in need of rapid diagnosis are many more who will have a lesser degree of kidney dysfunction, called Chronic Kidney Disease (CKD), that will place them at increased risk of cardiovascular disease and acute kidney injury.
Helen Meese CEng, MIMech, PhD, Head of Materials at the Institution of Mechanical Engineers (London, UK), said, “The QELFA device is a brilliant example of what's possible. Using an old technology like a pregnancy tester and combining it with nanotechnology, you have a device which could not only diagnose the million people in the UK who are unaware they have kidney disease, but also help doctors effectively monitor those undergoing treatment. It could also save the NHS millions of pounds a year. But although the UK has been at the forefront of nanotechnology development, we still lag behind in its commercialization and many people are still unsure of its potential. We must change this.”
Related Links:
Bio Nano Consulting
Institution of Mechanical Engineers
Latest Technology News
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







